Zhejiang Huahai Pharmaceutical Co., Ltd.SSE: 600521

(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Estimated Increase in Performance for the First Three Quarters of 2026

· Issued by Zhejiang Huahai Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600521 · · 3 pages · Chinese

Summary by 6ix AI

The company expects net profit attributable to shareholders to rise substantially, driven by strong sales in its raw materials and domestic formulation businesses, among other factors. The announcement includes a risk warning, stating there are no major uncertainties affecting the accuracy of the performance forecast. This filing serves as a preliminary performance forecast and the final figures will be disclosed in the official third-quarter report.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600521zhejiang-huahai-pharmaceutical-co-ltdannouncement-on-estimated-increase-in-performance-for-the-first-three-quarters-of-2026

Release

Announcement on Estimated Increase in Performance for the First Three Quarters of 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Zhejiang Huahai Pharmaceutical

Later from Zhejiang Huahai Pharmaceutical

All Zhejiang Huahai Pharmaceutical news releases